The 2024 Global Antibody-Drug Conjugates Report  

Gain comprehensive insights into the ADC market with our 2024 Global Antibody-Drug Conjugates Report. This in-depth analysis covers market trends, clinical development challenges, innovation opportunities, competitive dynamics, and strategic deals.

Key findings include:

• With 13 FDA-approved products treating over 20 cancer types, the ADC market is projected to grow from $10 billion in 2023 to $39 billion by 2030, driven by multiple blockbuster therapies, each expected to exceed $1 billion in annual sales.
• The development pipeline includes over 180 ADCs, with 80% targeting solid tumors. Innovation in conjugation technologies, linkers, binding moieties, and payload design, as well as investigation of novel antigens continues to enhance their therapeutic potential.
• The ADC sector has undergone substantial consolidation, driven by strategic mergers and acquisitions spearheaded by major pharmaceutical companies. These actions aim to enhance efficiency in global clinical development pipelines for next-generation ADCs while strengthening the commercial infrastructure for approved products.